ESR1 and breast cancer: In an ongoing clinical trial (NCT01953926), the HER2 inhibitor neratinib, administered together with fulvestrant, increased progression-free survival compared to neratinib alone in ER+/HER2-mutant metastatic BC patients pre-treated with endocrine therapy [29].